The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/ trastuzumab ) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase II trial.
 
Hong-Fei Gao
No Relationships to Disclose
 
Zhiyong Wu
No Relationships to Disclose
 
Ying Lin
No Relationships to Disclose
 
Xiangyang Song
No Relationships to Disclose
 
Yin Cao
No Relationships to Disclose
 
Zhenzhen Liu
No Relationships to Disclose
 
Qian-Jun Chen
No Relationships to Disclose
 
Liulu Zhang
No Relationships to Disclose
 
Ci-Qiu Yang
No Relationships to Disclose
 
Mei Yang
No Relationships to Disclose
 
Teng Zhu
No Relationships to Disclose
 
Jieqing Li
No Relationships to Disclose
 
Fei Ji
No Relationships to Disclose
 
Min-Yi Cheng
No Relationships to Disclose
 
Kun Wang
No Relationships to Disclose